Clinical Trial News and Research

RSS

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

28 Apr 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO Pharmaceuticals, Inc. today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011.

28 Apr 2011

Guided Therapeutics' cervical detection technology design, branding to be presented at ACOG

Guided Therapeutics, Inc., announced that it will present the new design and branding of its non-invasive and painless test for the early detection of cervical precancer at two upcoming international gynecology conferences.

28 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

GSN receives NIH grant for non-invasive prenatal test trial in genetic abnormalities

Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.

28 Apr 2011

Cotinine can reduce plaques linked with dementia and prevent memory loss

Cotinine, a compound derived from tobacco, reduced plaques associated with dementia and prevented memory loss in a mouse model of Alzheimer's disease, a study led by researchers at Bay Pines VA Healthcare System and the University of South Florida found.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

Trig Medical to launch new standard for labor progression management at ACOG 2011

Trig Medical, Inc. announces the U.S. launch of LaborPro®, the new standard for labor progression management, at the American Congress of Obstetricians and Gynecologists (ACOG) 2011 Annual Clinical Meeting, taking place April 30 – May 4, 2011 in Washington, D.C. Trig Medical will be demonstrating the LaborPro system in Booth #824 during exhibition hours.

28 Apr 2011

Neovasc 2010 consolidated net loss decreases to $2,630,885

Neovasc Inc., today announced financial results for the year ended December 31, 2010.

27 Apr 2011

Spectranetics revenue increases 5% to $30.4 million for first quarter 2011

Spectranetics Corporation today reported financial results for the quarter ended March 31, 2011.

27 Apr 2011

Advanced Orthopaedics & Spine Medicine to participate in iUni G2 knee implant trial

Dr. David Mack of Advanced Orthopaedics & Spine Medicine and North Cypress Medical Center are participating in a ten year follow-up trial of the ConforMIS iUni® G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

Performance Orthopedics to participate in iUni G2 knee implant trial

Dr. Gregory Martin of Performance Orthopedics of the Palm Beaches is participating in a ten year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Cancer researchers at hundreds of sites nationwide are about to launch a SWOG-led clinical trial that could keep thousands of breast cancer patients from getting chemotherapy that is unlikely to do them any good.

27 Apr 2011

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

27 Apr 2011

Brookside Surgery Center to participate in iUni G2 knee implant trial

Dr. Joseph Burkhardt of Brookside Surgery Center is participating in a ten year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF.

27 Apr 2011

Clinical Trial News and Research

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

Curis reports first quarter net loss of $6.8 million

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

AVEO reports total revenue of $133.6 million for first quarter 2011

Guided Therapeutics' cervical detection technology design, branding to be presented at ACOG

Positive results from Shire's Vyvanse clinical trial in schizophrenia

GSN receives NIH grant for non-invasive prenatal test trial in genetic abnormalities

Cotinine can reduce plaques linked with dementia and prevent memory loss

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Trig Medical to launch new standard for labor progression management at ACOG 2011

Neovasc 2010 consolidated net loss decreases to $2,630,885

Spectranetics revenue increases 5% to $30.4 million for first quarter 2011

Advanced Orthopaedics & Spine Medicine to participate in iUni G2 knee implant trial

Performance Orthopedics to participate in iUni G2 knee implant trial

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

Nationwide researchers to launch Oncotype DX test phase III trial in breast cancer

Boehringer Ingelheim initiates enrollment in BI 201335 Phase 3 clinical trial for chronic HCV

Brookside Surgery Center to participate in iUni G2 knee implant trial

IQ Therapeutics completes dosing in IQNLF Phase I trial for anthrax

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News